TrialSignal
Clinical trial intelligence report
A Randomized, Double-blind, Parallel Controlled, Phase I Three-arm Study, Comparing the PK, PD, Safety, and Immunogenicity of Pre- and Post-change CMAB807X, Post-change CMAB807X and Xgeva® in Healthy Chinese Male Subjects
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT05808673
Status
WITHDRAWN
Phase
PHASE1
Sponsor
Taizhou Mabtech Pharmaceutical Co.,Ltd
Executive brief
Investment-Ready Snapshot
This is a randomized, double-blinded, controlled Phase I three-arms study of CMAB807X administered by subcutaneous injection. This study will characterize the pharmacokinetic, pharmacodynamics, safety and immunogenicity of CMAB807X Pre- and Post-change in Manufacturing Site, and Post-change CMAB807X versus Xgeva® #Denosumab# in healthy male subjects after a single dose
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05808673
Indication
Healthy Volunteers
Modality
monoclonal antibody
Target
Post-change CMAB807X, Pre-change CMAB807X, Xgeva®
Intervention
Post-change CMAB807X, Pre-change CMAB807X, Xgeva®
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.